Barostim Late-Breaking Data from THT 2025: Roundtable Discussion with Dr. Phil Adamson 

Following THT 2025, Dr. Phil Adamson, Chief Medical Officer of CVRx, led a virtual roundtable discussion with Dr. Jacob Abraham, Dr. Dmitry Yaranov and Dr. Patrick McCann to review their data presentations from the meeting. 

• Baroreflex Activation Therapy improves cardiopulmonary exercise tolerance and aerobic capacity in heart failure with reduced ejection fraction
  Dmitry Yaranov, MD
• Impact of Barostim therapy on atrial fibrillation burden: A retrospective single-center study
  Patrick McCann, MD
• Baroreflex Activation Therapy reduces healthcare utilization in patients with heart failure
  Jacob Abraham, MD

Dr. Jacob Abraham, Dr. Dmitry Yaranov and Dr. Patrick McCann are paid consultants of CVRx.